Trial Outcomes & Findings for Perioperative Mental Health in Orthopedic Surgery (NCT NCT05697835)

NCT ID: NCT05697835

Last Updated: 2026-04-09

Results Overview

Change in PHQ-ADS (Patient Health Questionnaire Anxiety and Depression Scale) scores from baseline to 3 months postoperatively will be compared between the two study arms 3 months after surgery. PHQ-ADS is a composite measure of anxiety and depression. PHQ-ADS scores can range from 0 to 48 (with higher scores indicating more severe depression/anxiety)

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

116 participants

Primary outcome timeframe

Baseline and 3 months post-operatively

Results posted on

2026-04-09

Participant Flow

1,113 orthopedic patients were assessed for eligibility, 501 did not meet inclusion criteria, 386 declined participation, and 110 were excluded for other reasons.

Participant milestones

Participant milestones
Measure
Behavioral Activation and Medication Optimization
Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference \& health condition. Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained. Behavioral activation: The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values Medication optimzation: Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
Control (Treatment as Usual)
Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults. Care as usual: Care as usual, with written resources provided
Overall Study
STARTED
58
58
Overall Study
COMPLETED
58
56
Overall Study
NOT COMPLETED
0
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Behavioral Activation and Medication Optimization
Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference \& health condition. Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained. Behavioral activation: The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values Medication optimzation: Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
Control (Treatment as Usual)
Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults. Care as usual: Care as usual, with written resources provided
Overall Study
Lost to Follow-up
0
2

Baseline Characteristics

Perioperative Mental Health in Orthopedic Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Behavioral Activation and Medication Optimization
n=50 Participants
Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference \& health condition. Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained. Behavioral activation: The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values Medication optimzation: Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
Control (Treatment as Usual)
n=54 Participants
Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults. Care as usual: Care as usual, with written resources provided
Total
n=104 Participants
Total of all reporting groups
Age, Continuous
69.0 years
STANDARD_DEVIATION 6.4 • n=36 Participants
68.7 years
STANDARD_DEVIATION 5.4 • n=78 Participants
68.8 years
STANDARD_DEVIATION 5.9 • n=23 Participants
Sex: Female, Male
Female
27 Participants
n=36 Participants
46 Participants
n=78 Participants
73 Participants
n=23 Participants
Sex: Female, Male
Male
23 Participants
n=36 Participants
8 Participants
n=78 Participants
31 Participants
n=23 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=36 Participants
0 Participants
n=78 Participants
0 Participants
n=23 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
50 Participants
n=36 Participants
54 Participants
n=78 Participants
104 Participants
n=23 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=36 Participants
0 Participants
n=78 Participants
0 Participants
n=23 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=36 Participants
0 Participants
n=78 Participants
0 Participants
n=23 Participants
Race (NIH/OMB)
Asian
0 Participants
n=36 Participants
0 Participants
n=78 Participants
0 Participants
n=23 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=36 Participants
0 Participants
n=78 Participants
0 Participants
n=23 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=36 Participants
9 Participants
n=78 Participants
12 Participants
n=23 Participants
Race (NIH/OMB)
White
47 Participants
n=36 Participants
45 Participants
n=78 Participants
92 Participants
n=23 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=36 Participants
0 Participants
n=78 Participants
0 Participants
n=23 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=36 Participants
0 Participants
n=78 Participants
0 Participants
n=23 Participants
Region of Enrollment
United States
50 participants
n=36 Participants
54 participants
n=78 Participants
104 participants
n=23 Participants

PRIMARY outcome

Timeframe: Baseline and 3 months post-operatively

Change in PHQ-ADS (Patient Health Questionnaire Anxiety and Depression Scale) scores from baseline to 3 months postoperatively will be compared between the two study arms 3 months after surgery. PHQ-ADS is a composite measure of anxiety and depression. PHQ-ADS scores can range from 0 to 48 (with higher scores indicating more severe depression/anxiety)

Outcome measures

Outcome measures
Measure
Behavioral Activation and Medication Optimization
n=50 Participants
Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference \& health condition. Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained. Behavioral activation: The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values Medication optimzation: Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
Control (Treatment as Usual)
n=54 Participants
Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults. Care as usual: Care as usual, with written resources provided
PHQ-ADS (Patient Health Questionnaire Anxiety and Depression Scale)
Baseline
16.84 Points
Standard Error 1.02
19.35 Points
Standard Error 1.10
PHQ-ADS (Patient Health Questionnaire Anxiety and Depression Scale)
Month 1
11.26 Points
Standard Error 1.03
13.09 Points
Standard Error 1.10
PHQ-ADS (Patient Health Questionnaire Anxiety and Depression Scale)
Month 3
9.08 Points
Standard Error 1.03
10.48 Points
Standard Error 1.12

Adverse Events

Behavioral Activation and Medication Optimization

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control (Treatment as Usual)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Ryan Calfee, MD

Washinton University School of Medicine

Phone: 314-362-9369

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place